Highlights

  • EIQ shares fell 1.41% to $0.70 during the 22 September session, moving against the broader ASX tech rally.
  • The S&P/ASX 200 Info Tech index rose 3.56% in the session, while the broader S&P/ASX 200 added 0.21%.
  • The move follows Echo IQ's regulatory update, released on 17 September 2026, on its EchoSolv HF FDA 510(k) application.
  • The FDA issued a Not Substantially Equivalent determination, with the company outlining multiple potential pathways to pursue clearance.

Echo IQ Limited (ASX:EIQ) shares traded lower during the 22 September session, down 1.41% to $0.70 as of 10:32am, moving against the direction of the broader technology sector on the day. The S&P/ASX 200 Information Technology index (INDEXASX: XIJ) rose 3.56%, or 57.40 points, to 1,671.20 during the session, while the benchmark S&P/ASX 200 (INDEXASX: XJO) added 0.21%, or 18.60 points, to 8,750.50 over the same period.

The broader technology sector's advance has tracked an artificial intelligence-powered rally on Wall Street, where major US indices posted sharp gains in the 21 September close, with the Nasdaq Composite up 2.26%, the S&P 500 up 1.49% and the Dow Jones Industrial Average up 0.71%.

Latest Development

EIQ released an update on 17 September 2026, in which the AI and medical technology company provided detail on its engagement with the US Food and Drug Administration regarding its EchoSolv HF 510(k) application, following an initial announcement on 8 September 2026.

The company confirmed it had received the FDA's Not Substantially Equivalent determination for its initial EchoSolv HF submission. Echo IQ said its review of the FDA's feedback indicated the matters cited related to aspects of statistical analysis supporting clinical validation, rather than concerns regarding the underlying technology or core functionality of the EchoSolv HF device.

The company outlined that it is assessing multiple potential pathways to progress EchoSolv HF toward FDA clearance, including an administrative appeal of the determination, seeking a procedural review through the FDA Ombudsman, or submitting a new 510(k) application. It said work was underway with regulatory consultants and legal counsel to advance a path toward clearance, which it believes could potentially be achieved over coming quarters.

Echo IQ said there had been no material impact on its strategic partner agreements as a result of the regulatory update, including its existing arrangements with Advara HeartCare, Mayo Clinic and Pro Medicus Limited. The company's existing product, EchoSolv AS, used as a clinical decision support aid in detecting severe aortic stenosis, remains FDA-cleared and is unaffected by the update concerning EchoSolv HF.

Catalysts to Watch Out

Clarity on which regulatory pathway the company chooses to pursue for EchoSolv HF, whether an administrative appeal, FDA Ombudsman review, or a new 510(k) submission, will be a key near-term update for the market to watch.

Resolution of the statistical analysis matters cited by the FDA in its determination, which the company has said does not extend to concerns about the underlying technology, could support a faster path back toward clearance if addressed satisfactorily.

The status of the company's convertible note arrangement and proposed commercial Partnership with Pro Medicus Limited, including a further A$10 million Investment Tranche the company has said is conditional on FDA clearance of EchoSolv HF, is directly tied to the regulatory outcome.

Broader developments relating to the proposed CMS Calendar Year 2027 OPPS rule and potential Software as a Medical Service payment methodology, referenced by the company as relevant to EchoSolv's reimbursement eligibility, remain an area to track independent of the FDA clearance process.

Risks and Uncertainty

The company has explicitly flagged the risk that a revised or new FDA submission may not be made or may not succeed, and that clearance may not be obtained within any particular timeframe, or at all.

A further A$10 million investment tranche from Pro Medicus is conditional on FDA clearance of EchoSolv HF, meaning delays or an unsuccessful outcome to the regulatory process could affect this funding component.

The regulatory pathways the company is assessing, including administrative appeal and Ombudsman review, do not have strictly defined timelines, introducing uncertainty around when a resolution might be reached.

As an early-commercialisation medical technology company, EIQ's share price can exhibit heightened sensitivity to regulatory newsflow, and further updates on the EchoSolv HF pathway could produce continued volatility.

The Bottom Line

EIQ shares declined on 22 September, moving against the direction of a broader ASX technology rally, following the company's update on the regulatory status of its EchoSolv HF FDA application. While the company has characterised the issues raised by the FDA as limited to statistical analysis matters rather than the underlying technology, the path to clearance now depends on which of several pathways the company pursues and how quickly it can be resolved. Regulatory pathway clarity, the status of the Pro Medicus partnership, and progress on reimbursement policy are likely to remain the key factors shaping the stock from here.